Clinical Trial Search

Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants

Primary: Maximum Tolerated Dose (MTD) of RENCA Macrobeads — NA RENCA Macrobeads/kg

Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants

Primary: Overall Survival — 13.43; 7.62 months

Primary: Maximum Tolerated Dose (MTD) — 2 # of cells x 10^11

Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg

Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…

Primary: Number of Participants With Brachyury-Specific T-cell Responses — 1; 0; 4; 1 Participants

Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…

Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL

Primary: Clinical Tumor Regression — 1 Participants

Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…

Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT

Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants

Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…

Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants

Primary: Number of Participants With Cardiac Toxicity — 6; 7; 6; 6 Participants

Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale

Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants

Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…

Primary: Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products — 9 participants

Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants

Primary: Percentage of Participants With a Response — 10; 50 percentage of participants

Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05

Primary: Number of Participants With Serious and Non-serious Adverse Events — 6; 4 Participants

Primary: Treatment-related Adverse Events — 19; 103; 85 Number of Treatment-related Adverse Even

Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml

Primary: Study Data and Samples Were Used for CancerSEEK Assay Development — 712; 3870; 5; 14 Participants

Primary: Toxicity — 5 participants

Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027